A study of YL-13027 and/or HY-0102 with chemo for metastatic pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests two new drugs, YL-13027 and HY-0102, when given together with standard chemotherapy (AG regimen) for people whose pancreatic cancer has spread to other parts of the body. The goal is to see if adding these drugs helps shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a confirmed diagnosis of metastatic pancreatic ductal adenocarcinoma (cancer that has spread).
- You have at least one tumor that can be measured on a scan (CT or MRI).
- You are in good enough health to be up and about (ECOG score 0 or 1) and expected to live at least 3 months.
- Your organs (like liver, kidneys, bone marrow) are functioning well enough for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three drugs (QL1706, chidamide, and AG) as the very first treatment for people with metastatic pancreatic cancer. The goal is to see if this combination is safe and effective, and it may offer a new option for those who have not had any prior therapy.
This trial tests a combination of three drugs (gemcitabine, erlotinib, and nab-paclitaxel) for people with a specific type of pancreatic cancer called 'basal-like' PDAC. It aims to see if this targeted approach works better than standard treatment.
This trial tests a new drug, LM-302, combined with gemcitabine for people with a specific type of advanced pancreatic cancer that has not responded to or stopped working on first-line treatment. The goal is to see if the combination is safe and effective.
This trial tests a new treatment called QLS31905 plus chemotherapy against a placebo plus chemotherapy for people with advanced pancreatic cancer that hasn't been treated yet. It aims to see if the new combination works better.
This Phase 2 study compares two chemotherapy combinations to treat metastatic pancreatic cancer that has progressed after gemcitabine (with or without Abraxane). It aims to see which combination works better and is tolerable for people with measurable disease.
This study compares two chemotherapy combinations for people with advanced (locally advanced or metastatic) pancreatic cancer that hasn't been treated yet. The goal is to see which combination works better and has fewer side effects.
Hear when a new Metastatic Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.